within Pharmacolibrary.Drugs.ATC.N;

model N02CD06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 0.000245,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005016666666666667,
    Tlag           = 60.0,            
    Vdp             = 0.037,
    k12             = 9.55,
    k21             = 9.55
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CD06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rimegepant is an orally administered, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute and preventive treatment of migraine in adults. It is an FDA-approved medication that reduces the occurrence and severity of migraine attacks by blocking the binding of CGRP to its receptor.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after administration of a single oral dose in the fasted state.</p><h4>References</h4><ol><li><p>Bhardwaj, R, et al., &amp; Bertz, RJ (2023). Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants. <i>Headache</i> 63(5) 652–662. DOI:<a href=\"https://doi.org/10.1111/head.14512\">10.1111/head.14512</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37140071/\">https://pubmed.ncbi.nlm.nih.gov/37140071</a></p></li><li><p>Bhardwaj, R, et al., &amp; Bertz, R (2022). P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. <i>Clinical pharmacology in drug development</i> 11(7) 889–897. DOI:<a href=\"https://doi.org/10.1002/cpdd.1088\">10.1002/cpdd.1088</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35304977/\">https://pubmed.ncbi.nlm.nih.gov/35304977</a></p></li><li><p>Bertz, R, et al., &amp; Croop, R (2023). A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants. <i>Cephalalgia : an international journal of headache</i> 43(6) 3331024231179131–None. DOI:<a href=\"https://doi.org/10.1177/03331024231179131\">10.1177/03331024231179131</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37282507/\">https://pubmed.ncbi.nlm.nih.gov/37282507</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CD06;
